The impact of peripheral arterial disease on left ventricular assist device implantation: A propensity‐matched analysis of the nationwide inpatient sample database
Left ventricular assist device (LVAD) candidacy screening includes evaluation for peripheral arterial disease (PAD). However, given current evidence, the impact of PAD on post‐LVAD complications remains unknown. The National Inpatient Sample (NIS) database (2002‐2017) was utilized to identify all LV...
Gespeichert in:
Veröffentlicht in: | Artificial organs 2021-08, Vol.45 (8), p.838-844 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 844 |
---|---|
container_issue | 8 |
container_start_page | 838 |
container_title | Artificial organs |
container_volume | 45 |
creator | Ullah, Waqas Zahid, Salman Thalambedu, Nishant Khan, Maria Massey, Howard Haas, Donald Tchantchaleishvili, Vakhtang Rame, Eduardo |
description | Left ventricular assist device (LVAD) candidacy screening includes evaluation for peripheral arterial disease (PAD). However, given current evidence, the impact of PAD on post‐LVAD complications remains unknown. The National Inpatient Sample (NIS) database (2002‐2017) was utilized to identify all LVAD cases. The in‐hospital safety endpoints included major cardiovascular adverse events and its components. A propensity‐matched analysis was used to obtain adjusted odds ratios (aOR). A subgroup analysis of patients with diabetes mellitus (DM) with PAD was also performed. A total of 27 424 patients with LVAD implantation (PAD: 516 [1.8%] and no‐PAD 26 908 [98.2%]) were included. There were significant intergroup differences in the demographics and baseline comorbidities. A weighted sample of 1053 (no‐PAD 537, PAD 516) propensity‐matched population was selected. The adjusted odds for in‐hospital mortality (aOR 1.7; 95% CI, 1.2‐2.44, P = .004) were found to be significantly higher for LVAD‐patients with PAD. There was no significant difference in the adjusted odds of MACE (aOR 1.16, 95% CI 0.87‐1.5), postprocedure bleeding (aOR 0.88, 95% CI 0.62‐1.26, P = .54) and risk of pneumonia (aOR 0.67, 95% CI 0.44‐1.15, P = .63) between the two groups. A selected cohort of DM‐only population (7339) consistently showed a higher adjusted mortality rate in PAD patients with LVAD implantation (aOR 2.3, 95% CI 1.2‐4.47, P = .01). The rate of MACE (P = .17), myocardial infarction (P = .12), stroke (P = .60), postprocedural (0.10), and major bleeding (P = .51) remained identical between patients with PAD and those with no‐PAD. PAD confers an increased risk of in‐hospital all‐cause mortality in patients undergoing LVAD implantation. This risk increases further in patients with a concomitant diagnosis of DM.
Forest plot showing the propensity‐matched estimate of adjusted odds ratios for in‐hospital outcomes between PAD vs no PAD groups undergoing LVAD implantation. |
doi_str_mv | 10.1111/aor.13934 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2487749226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2553615594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3134-b0117b6158795956a38e4ab2069935cd28177735cfce7fe45d8f61c67a1da2f03</originalsourceid><addsrcrecordid>eNp1kc9q3DAQxkVpaLZpD32BIuglPTiRLEuye1tC0hYCgZJCb2Ysj1kF_6skJ-ytj9CXyIvlSTrZTXsoRBfNwG--b4aPsXdSnEh6pzCFE6kqVbxgK6lznUldFS_ZSkgjMm2KH4fsdYw3QghbCPOKHSqldZXrfMXurzfI_TCDS3zq-IzBzxsM0HMIiRoqWh8RIvJp5D12id_imIJ3Sw-BQ4w-Jt7irXc7nR7GBMlP4ye-5nOYZhyjT9uHX78HSG6DLYcR-i1NPdolMh93-J1vaX6cqSF5HoGkkLeQoCHvN-yggz7i26f_iH2_OL8--5JdXn3-era-zJySqsgaIaVtjNSlrXSlDagSC2hyYapKadfmpbTWUtU5tB0Wui07I52xIFvIO6GO2PFelzb_uWBM9eCjw56uwmmJdV6U1hZVnhtCP_yH3kxLoNuI0lrREpQBUR_3lAtTjAG7eg5-gLCtpagfs6spu3qXHbHvnxSXZsD2H_k3LAJO98Cd73H7vFK9vvq2l_wDZZ-nDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553615594</pqid></control><display><type>article</type><title>The impact of peripheral arterial disease on left ventricular assist device implantation: A propensity‐matched analysis of the nationwide inpatient sample database</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ullah, Waqas ; Zahid, Salman ; Thalambedu, Nishant ; Khan, Maria ; Massey, Howard ; Haas, Donald ; Tchantchaleishvili, Vakhtang ; Rame, Eduardo</creator><creatorcontrib>Ullah, Waqas ; Zahid, Salman ; Thalambedu, Nishant ; Khan, Maria ; Massey, Howard ; Haas, Donald ; Tchantchaleishvili, Vakhtang ; Rame, Eduardo</creatorcontrib><description>Left ventricular assist device (LVAD) candidacy screening includes evaluation for peripheral arterial disease (PAD). However, given current evidence, the impact of PAD on post‐LVAD complications remains unknown. The National Inpatient Sample (NIS) database (2002‐2017) was utilized to identify all LVAD cases. The in‐hospital safety endpoints included major cardiovascular adverse events and its components. A propensity‐matched analysis was used to obtain adjusted odds ratios (aOR). A subgroup analysis of patients with diabetes mellitus (DM) with PAD was also performed. A total of 27 424 patients with LVAD implantation (PAD: 516 [1.8%] and no‐PAD 26 908 [98.2%]) were included. There were significant intergroup differences in the demographics and baseline comorbidities. A weighted sample of 1053 (no‐PAD 537, PAD 516) propensity‐matched population was selected. The adjusted odds for in‐hospital mortality (aOR 1.7; 95% CI, 1.2‐2.44, P = .004) were found to be significantly higher for LVAD‐patients with PAD. There was no significant difference in the adjusted odds of MACE (aOR 1.16, 95% CI 0.87‐1.5), postprocedure bleeding (aOR 0.88, 95% CI 0.62‐1.26, P = .54) and risk of pneumonia (aOR 0.67, 95% CI 0.44‐1.15, P = .63) between the two groups. A selected cohort of DM‐only population (7339) consistently showed a higher adjusted mortality rate in PAD patients with LVAD implantation (aOR 2.3, 95% CI 1.2‐4.47, P = .01). The rate of MACE (P = .17), myocardial infarction (P = .12), stroke (P = .60), postprocedural (0.10), and major bleeding (P = .51) remained identical between patients with PAD and those with no‐PAD. PAD confers an increased risk of in‐hospital all‐cause mortality in patients undergoing LVAD implantation. This risk increases further in patients with a concomitant diagnosis of DM.
Forest plot showing the propensity‐matched estimate of adjusted odds ratios for in‐hospital outcomes between PAD vs no PAD groups undergoing LVAD implantation.</description><identifier>ISSN: 0160-564X</identifier><identifier>EISSN: 1525-1594</identifier><identifier>DOI: 10.1111/aor.13934</identifier><identifier>PMID: 33559252</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adverse events ; Bleeding ; Cerebral infarction ; Complications ; Demographics ; Demography ; Diabetes Complications - physiopathology ; Diabetes mellitus ; Endpoint Determination ; Female ; Heart ; Heart-Assist Devices ; Hospital Mortality ; Humans ; Implantation ; left ventricular assist device ; Male ; Middle Aged ; Mortality ; Myocardial infarction ; Patient safety ; Patients ; peripheral arterial disease ; Peripheral Arterial Disease - complications ; Peripheral Arterial Disease - physiopathology ; Propensity Score ; Retrospective Studies ; Risk ; Risk Factors ; Subgroups ; Survival Analysis ; United States ; Ventricle</subject><ispartof>Artificial organs, 2021-08, Vol.45 (8), p.838-844</ispartof><rights>2021 International Center for Artificial Organs and Transplantation and Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3134-b0117b6158795956a38e4ab2069935cd28177735cfce7fe45d8f61c67a1da2f03</cites><orcidid>0000-0002-4357-3533 ; 0000-0002-4850-0309</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faor.13934$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faor.13934$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33559252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ullah, Waqas</creatorcontrib><creatorcontrib>Zahid, Salman</creatorcontrib><creatorcontrib>Thalambedu, Nishant</creatorcontrib><creatorcontrib>Khan, Maria</creatorcontrib><creatorcontrib>Massey, Howard</creatorcontrib><creatorcontrib>Haas, Donald</creatorcontrib><creatorcontrib>Tchantchaleishvili, Vakhtang</creatorcontrib><creatorcontrib>Rame, Eduardo</creatorcontrib><title>The impact of peripheral arterial disease on left ventricular assist device implantation: A propensity‐matched analysis of the nationwide inpatient sample database</title><title>Artificial organs</title><addtitle>Artif Organs</addtitle><description>Left ventricular assist device (LVAD) candidacy screening includes evaluation for peripheral arterial disease (PAD). However, given current evidence, the impact of PAD on post‐LVAD complications remains unknown. The National Inpatient Sample (NIS) database (2002‐2017) was utilized to identify all LVAD cases. The in‐hospital safety endpoints included major cardiovascular adverse events and its components. A propensity‐matched analysis was used to obtain adjusted odds ratios (aOR). A subgroup analysis of patients with diabetes mellitus (DM) with PAD was also performed. A total of 27 424 patients with LVAD implantation (PAD: 516 [1.8%] and no‐PAD 26 908 [98.2%]) were included. There were significant intergroup differences in the demographics and baseline comorbidities. A weighted sample of 1053 (no‐PAD 537, PAD 516) propensity‐matched population was selected. The adjusted odds for in‐hospital mortality (aOR 1.7; 95% CI, 1.2‐2.44, P = .004) were found to be significantly higher for LVAD‐patients with PAD. There was no significant difference in the adjusted odds of MACE (aOR 1.16, 95% CI 0.87‐1.5), postprocedure bleeding (aOR 0.88, 95% CI 0.62‐1.26, P = .54) and risk of pneumonia (aOR 0.67, 95% CI 0.44‐1.15, P = .63) between the two groups. A selected cohort of DM‐only population (7339) consistently showed a higher adjusted mortality rate in PAD patients with LVAD implantation (aOR 2.3, 95% CI 1.2‐4.47, P = .01). The rate of MACE (P = .17), myocardial infarction (P = .12), stroke (P = .60), postprocedural (0.10), and major bleeding (P = .51) remained identical between patients with PAD and those with no‐PAD. PAD confers an increased risk of in‐hospital all‐cause mortality in patients undergoing LVAD implantation. This risk increases further in patients with a concomitant diagnosis of DM.
Forest plot showing the propensity‐matched estimate of adjusted odds ratios for in‐hospital outcomes between PAD vs no PAD groups undergoing LVAD implantation.</description><subject>Adverse events</subject><subject>Bleeding</subject><subject>Cerebral infarction</subject><subject>Complications</subject><subject>Demographics</subject><subject>Demography</subject><subject>Diabetes Complications - physiopathology</subject><subject>Diabetes mellitus</subject><subject>Endpoint Determination</subject><subject>Female</subject><subject>Heart</subject><subject>Heart-Assist Devices</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Implantation</subject><subject>left ventricular assist device</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Patient safety</subject><subject>Patients</subject><subject>peripheral arterial disease</subject><subject>Peripheral Arterial Disease - complications</subject><subject>Peripheral Arterial Disease - physiopathology</subject><subject>Propensity Score</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>Subgroups</subject><subject>Survival Analysis</subject><subject>United States</subject><subject>Ventricle</subject><issn>0160-564X</issn><issn>1525-1594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9q3DAQxkVpaLZpD32BIuglPTiRLEuye1tC0hYCgZJCb2Ysj1kF_6skJ-ytj9CXyIvlSTrZTXsoRBfNwG--b4aPsXdSnEh6pzCFE6kqVbxgK6lznUldFS_ZSkgjMm2KH4fsdYw3QghbCPOKHSqldZXrfMXurzfI_TCDS3zq-IzBzxsM0HMIiRoqWh8RIvJp5D12id_imIJ3Sw-BQ4w-Jt7irXc7nR7GBMlP4ye-5nOYZhyjT9uHX78HSG6DLYcR-i1NPdolMh93-J1vaX6cqSF5HoGkkLeQoCHvN-yggz7i26f_iH2_OL8--5JdXn3-era-zJySqsgaIaVtjNSlrXSlDagSC2hyYapKadfmpbTWUtU5tB0Wui07I52xIFvIO6GO2PFelzb_uWBM9eCjw56uwmmJdV6U1hZVnhtCP_yH3kxLoNuI0lrREpQBUR_3lAtTjAG7eg5-gLCtpagfs6spu3qXHbHvnxSXZsD2H_k3LAJO98Cd73H7vFK9vvq2l_wDZZ-nDw</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Ullah, Waqas</creator><creator>Zahid, Salman</creator><creator>Thalambedu, Nishant</creator><creator>Khan, Maria</creator><creator>Massey, Howard</creator><creator>Haas, Donald</creator><creator>Tchantchaleishvili, Vakhtang</creator><creator>Rame, Eduardo</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4357-3533</orcidid><orcidid>https://orcid.org/0000-0002-4850-0309</orcidid></search><sort><creationdate>202108</creationdate><title>The impact of peripheral arterial disease on left ventricular assist device implantation: A propensity‐matched analysis of the nationwide inpatient sample database</title><author>Ullah, Waqas ; Zahid, Salman ; Thalambedu, Nishant ; Khan, Maria ; Massey, Howard ; Haas, Donald ; Tchantchaleishvili, Vakhtang ; Rame, Eduardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3134-b0117b6158795956a38e4ab2069935cd28177735cfce7fe45d8f61c67a1da2f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Bleeding</topic><topic>Cerebral infarction</topic><topic>Complications</topic><topic>Demographics</topic><topic>Demography</topic><topic>Diabetes Complications - physiopathology</topic><topic>Diabetes mellitus</topic><topic>Endpoint Determination</topic><topic>Female</topic><topic>Heart</topic><topic>Heart-Assist Devices</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Implantation</topic><topic>left ventricular assist device</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Patient safety</topic><topic>Patients</topic><topic>peripheral arterial disease</topic><topic>Peripheral Arterial Disease - complications</topic><topic>Peripheral Arterial Disease - physiopathology</topic><topic>Propensity Score</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>Subgroups</topic><topic>Survival Analysis</topic><topic>United States</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ullah, Waqas</creatorcontrib><creatorcontrib>Zahid, Salman</creatorcontrib><creatorcontrib>Thalambedu, Nishant</creatorcontrib><creatorcontrib>Khan, Maria</creatorcontrib><creatorcontrib>Massey, Howard</creatorcontrib><creatorcontrib>Haas, Donald</creatorcontrib><creatorcontrib>Tchantchaleishvili, Vakhtang</creatorcontrib><creatorcontrib>Rame, Eduardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Artificial organs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ullah, Waqas</au><au>Zahid, Salman</au><au>Thalambedu, Nishant</au><au>Khan, Maria</au><au>Massey, Howard</au><au>Haas, Donald</au><au>Tchantchaleishvili, Vakhtang</au><au>Rame, Eduardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of peripheral arterial disease on left ventricular assist device implantation: A propensity‐matched analysis of the nationwide inpatient sample database</atitle><jtitle>Artificial organs</jtitle><addtitle>Artif Organs</addtitle><date>2021-08</date><risdate>2021</risdate><volume>45</volume><issue>8</issue><spage>838</spage><epage>844</epage><pages>838-844</pages><issn>0160-564X</issn><eissn>1525-1594</eissn><abstract>Left ventricular assist device (LVAD) candidacy screening includes evaluation for peripheral arterial disease (PAD). However, given current evidence, the impact of PAD on post‐LVAD complications remains unknown. The National Inpatient Sample (NIS) database (2002‐2017) was utilized to identify all LVAD cases. The in‐hospital safety endpoints included major cardiovascular adverse events and its components. A propensity‐matched analysis was used to obtain adjusted odds ratios (aOR). A subgroup analysis of patients with diabetes mellitus (DM) with PAD was also performed. A total of 27 424 patients with LVAD implantation (PAD: 516 [1.8%] and no‐PAD 26 908 [98.2%]) were included. There were significant intergroup differences in the demographics and baseline comorbidities. A weighted sample of 1053 (no‐PAD 537, PAD 516) propensity‐matched population was selected. The adjusted odds for in‐hospital mortality (aOR 1.7; 95% CI, 1.2‐2.44, P = .004) were found to be significantly higher for LVAD‐patients with PAD. There was no significant difference in the adjusted odds of MACE (aOR 1.16, 95% CI 0.87‐1.5), postprocedure bleeding (aOR 0.88, 95% CI 0.62‐1.26, P = .54) and risk of pneumonia (aOR 0.67, 95% CI 0.44‐1.15, P = .63) between the two groups. A selected cohort of DM‐only population (7339) consistently showed a higher adjusted mortality rate in PAD patients with LVAD implantation (aOR 2.3, 95% CI 1.2‐4.47, P = .01). The rate of MACE (P = .17), myocardial infarction (P = .12), stroke (P = .60), postprocedural (0.10), and major bleeding (P = .51) remained identical between patients with PAD and those with no‐PAD. PAD confers an increased risk of in‐hospital all‐cause mortality in patients undergoing LVAD implantation. This risk increases further in patients with a concomitant diagnosis of DM.
Forest plot showing the propensity‐matched estimate of adjusted odds ratios for in‐hospital outcomes between PAD vs no PAD groups undergoing LVAD implantation.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33559252</pmid><doi>10.1111/aor.13934</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4357-3533</orcidid><orcidid>https://orcid.org/0000-0002-4850-0309</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0160-564X |
ispartof | Artificial organs, 2021-08, Vol.45 (8), p.838-844 |
issn | 0160-564X 1525-1594 |
language | eng |
recordid | cdi_proquest_miscellaneous_2487749226 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Adverse events Bleeding Cerebral infarction Complications Demographics Demography Diabetes Complications - physiopathology Diabetes mellitus Endpoint Determination Female Heart Heart-Assist Devices Hospital Mortality Humans Implantation left ventricular assist device Male Middle Aged Mortality Myocardial infarction Patient safety Patients peripheral arterial disease Peripheral Arterial Disease - complications Peripheral Arterial Disease - physiopathology Propensity Score Retrospective Studies Risk Risk Factors Subgroups Survival Analysis United States Ventricle |
title | The impact of peripheral arterial disease on left ventricular assist device implantation: A propensity‐matched analysis of the nationwide inpatient sample database |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T23%3A31%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20peripheral%20arterial%20disease%20on%20left%20ventricular%20assist%20device%20implantation:%20A%20propensity%E2%80%90matched%20analysis%20of%20the%20nationwide%20inpatient%20sample%20database&rft.jtitle=Artificial%20organs&rft.au=Ullah,%20Waqas&rft.date=2021-08&rft.volume=45&rft.issue=8&rft.spage=838&rft.epage=844&rft.pages=838-844&rft.issn=0160-564X&rft.eissn=1525-1594&rft_id=info:doi/10.1111/aor.13934&rft_dat=%3Cproquest_cross%3E2553615594%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2553615594&rft_id=info:pmid/33559252&rfr_iscdi=true |